GMP-Grade Exosome Manufacturing
OverviewServicesAdvantagesApplicationsFAQs
Overview
GMP-Grade Exosome Manufacturing is the comprehensive framework that transforms a microbial production strain into a regulatory-compliant exosome drug substance or drug product ready for clinical investigation. Unlike isolated unit operations, end-to-end manufacturing demands tight integration across upstream fermentation, downstream purification, and QC release testing—each stage feeding the next with documented, traceable, and quality-assured material. The strength of the manufacturing platform lies not in any single step, but in the way each step is designed to protect the critical quality attributes of the final vesicle product.
At Creative BioMart Microbe, we offer a unified GMP manufacturing service for bacterial and fungal extracellular vesicles, combining upstream fermentation and culture, downstream purification and bulk drug-substance formulation, and full QC release testing under a single quality management system. Our approach is purpose-built for microbial exosomes: we account for the distinct cell-envelope architectures of Gram-negative, Gram-positive, and fungal hosts, the unique size and charge distributions of bacterial outer membrane vesicles (OMVs), cytoplasmic membrane vesicles (CMVs), and fungal EVs, and the absence of pharmacopoeial monographs for these novel products. Projects can enter at Research-Grade and progress through Food-Grade and Cosmetic-Grade to full GMP-Grade production without redundant revalidation. Contact us to discuss your GMP manufacturing program for microbial exosomes.
Figure 1. Integrated GMP-Grade Exosome Manufacturing workflow spanning upstream fermentation, downstream purification, and QC release testing.
Services
GMP Manufacturing Service Modules
Our GMP-Grade Exosome Manufacturing platform is organized into three specialized, interconnected service modules. Each module can be contracted as part of a complete program or engaged individually to complement your existing process development work.
Downstream Purification
Primary clarification, TFF concentration and diafiltration, orthogonal chromatography, virus clearance, sterile filtration, and bulk drug-substance formulation.
View Details
QC Release Testing
Identity, purity, potency, and safety testing; method qualification; stability programs; and QA batch release with certificate of analysis.
View Details
Program Engagement & Project Lifecycle
Every GMP manufacturing program begins with a client consultation and technical alignment phase. We review your target product profile, regulatory pathway, strain characteristics, and intended clinical application to define the appropriate manufacturing strategy and quality requirements. From there, the program progresses through process development, engineering runs, process validation, and GMP production, with each module contributing to the final regulatory documentation package.
Quality Management System
- Phase-appropriate quality oversight across upstream, downstream, and QC operations.
- Independent QA review and batch disposition for every GMP manufacturing campaign.
- Documented change control, deviation management, and CAPA systems integrated with batch release.
- Raw material qualification and vendor audit program for media components, chromatography resins, filters, and excipients.
- Equipment qualification, calibration, and preventive maintenance supporting GMP inspection readiness.
- Environmental monitoring and contamination control strategies for controlled manufacturing areas.
- Data integrity controls with audit trails, electronic signatures, and secure data archival.
Regulatory Documentation
- Manufacturing process description and flow diagram suitable for IND/IMPD Module 3.
- Facility and equipment qualification summaries.
- Process validation protocol and report with predefined acceptance criteria.
- Executed master batch records and in-process monitoring data.
- Certificates of analysis for process intermediates, bulk drug substance, and final product.
- Viral clearance and safety testing summaries.
- Stability protocol and report for shelf-life justification.
Our Advantages
- Integrated End-to-End Platform — Upstream, downstream, and QC operate under a single quality system, eliminating hand-off gaps, reducing specification mismatches, and accelerating batch release.
- Microbial Exosome Specialization — Our platform is purpose-built for bacterial OMVs, Gram-positive CMVs, and fungal EVs rather than adapted from mammalian cell-culture workflows.
- Four-Tier Compliance Continuity — Development work at Research, Food-Grade, and Cosmetic-Grade tiers can progress directly into GMP campaigns, preserving data and avoiding redundant revalidation.
- Regulatory-Ready Quality Systems — Every GMP program generates structured documentation, batch records, and certificates supporting IND, IMPD, and BLA submissions.
- Flexible Engagement Models — We support full end-to-end programs, single-module campaigns, or integration with your existing process development and manufacturing partners.
Applications
mEV Therapeutic Development
GMP manufacturing of microbial exosomes as active pharmaceutical ingredients for IND-enabling and clinical-stage therapeutic programs.
OMV-Based Vaccine Manufacturing
GMP-compliant OMV production and purification for prophylactic and therapeutic vaccine drug substance.
mEV Drug Delivery Systems
GMP manufacturing of microbial exosomes as targeted nanocarriers for nucleic acids, small molecules, and protein therapeutics.
BEV Reference Standards & Research Reagents
Well-characterized GMP-grade mEV batches as reference materials and research reagents for assay development and standardization.
FAQs
Q: What is included in a GMP-Grade Exosome Manufacturing program?
A: A complete program covers upstream fermentation and culture, downstream purification and bulk drug-substance formulation, and QC release testing with method qualification and batch disposition. Each module can also be engaged independently if you already have a developed process upstream or downstream.
Q: Can I start with a lower compliance tier and move to GMP later?
A: Yes. Our four-tier compliance framework allows development work at Research, Food-Grade, and Cosmetic-Grade levels to feed into GMP campaigns with controlled tech transfer and comparability studies, reducing redundant development and preserving your earlier data investment.
Q: Which microbial production systems do you support?
A: We support Gram-negative bacteria, Gram-positive bacteria, and fungal hosts commonly used for microbial exosome production. Strains must be within our facility's biosafety containment capability and accompanied by complete documentation. High-containment pathogens are not currently supported.
Q: What distinguishes microbial exosome GMP manufacturing from mammalian EV manufacturing?
A: Microbial exosomes present unique challenges related to cell-wall and outer-membrane architecture, lipopolysaccharide or lipoteichoic acid content, particle size heterogeneity, and the absence of established pharmacopoeial methods. Our platform is built around these differences rather than adapting mammalian cell-culture workflows.
Q: What regulatory documentation is provided for a GMP program?
A: Every GMP program delivers manufacturing process descriptions, facility and equipment qualification summaries, process validation reports, executed batch records, in-process data, certificates of analysis, safety and viral clearance summaries, and stability documentation structured for IND, IMPD, or BLA submissions.
Q: How do I know which service module I need?
A: During the initial consultation, we review your current process stage, target product profile, and regulatory goals. Clients with a developed upstream process often need downstream purification and QC; clients with a new strain typically start with upstream fermentation and culture. We design the program scope around your specific needs.
Related Services:
